NSE: LUPIN | BSE: 500257

Falling Comet

Download real time

1894.70 -0.10 (-0.01%)

1.5M NSE+BSE Volume

NSE 11 Jul, 2025 3:31 PM (IST)

86,534

Market Cap

High in industry

0.8

Beta 1Year

Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

03 Jul 2025

1894.70

-0.01%

Lupin (BUY): Lupin carves out Consumer Healthcare business

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's OTC carve-out won't significantly impact financials, but aims to double OTC sales by sharpening focus

Number of FII/FPI investors increased from 964 to 979 in Mar 2025 qtr.

Lupin Ltd.

16 May 2025

1894.70

-0.01%

Lupin (LPC IN) Q4FY25 Result Update Strong US...

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

Lupin's (LPC) Q4FY25 EBITDA was at Rs13bn (up 30% YoY) ~10% beat to our estimates on the back of higher US sales supported by niche launches. GMs improved YoY. LPC saw remarkable turnaround in profitability with ~2x jump in EBITDA over FY23-24 aided by better product mix, continued niche launches in the US, clearance from USFDA for facilities, domestic formulations regaining momentum and cost optimization measures. We expect margins to sustain given a strong pipeline in the US. Our FY26E stands increase by 5% as we factor...

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

15 May 2025

1894.70

-0.01%

Niche products and superior execution lead to robust 4Q and FY25 performance

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered slightly better-than-expected revenue, EBITDA, and PAT for the quarter (4% beat). LPC continues to track well in the US generics segment (40% of 4Q sales), clocking the highest quarterly run-rate of USD245m over the past 24 quarters.

BOB Capital Markets Ltd. released a Buy report for Lupin Ltd. with a price target of 2626.0 on 03 Jul, 2025.

Lupin Ltd.

13 Mar 2025, 12:00AM

1894.70

-0.01%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. has an average target of 2429.71 from 7 brokers.

Lupin Ltd.

13 Feb 2025, 12:00AM

1894.70

-0.01%

Lupin (BUY): High-margin US region to have growth visibility till FY27

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

US sales cc quarterly run rate at its highest-ever level of US$ 235mn, expect to inch up to US$ 250mn in FY26E and US$ 280mn in FY27E

BOB Capital Markets Ltd. released a Buy report for Lupin Ltd. with a price target of 2626.0 on 03 Jul, 2025.

Lupin Ltd.

13 Feb 2025, 12:00AM

1894.70

-0.01%

LUPIN LTD

Buy: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

BOB Capital Markets Ltd. released a Buy report for Lupin Ltd. with a price target of 2626.0 on 03 Jul, 2025.

Lupin Ltd.

13 Feb 2025, 12:00AM

1894.70

-0.01%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

30 Dec 2024

1894.70

-0.01%

Delay in approval for Amneal's gProAir an unexpected positive

Buy: Lupin Ltd.

Emkay

In Teva’s litigation with Amneal which blocked Amneal’s launch of gProAir, the US Court of Appeals had recently asked Teva to delist its patents in contention. While the ruling was expected to clear the way for Amneal’s launch of gProAir, Teva has now filed a petition seeking an en banc rehearing.